18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers

Abstract Objective 18 F-flortaucipir (Tauvid™) is an 18 F-labeled diagnostic positron emission tomography (PET) radiopharmaceutical, which was developed to detect tau pathology in the brain and to estimate the density and/or distribution of aggregated tau neurofibrillary tangles for patients being evaluated for Alzheimer’s disease (AD). The objective of this article is to report findings from two studies. The primary objective of the first ( dose and biodistribution) study was to investigate the consistency of 18 F-flortaucipir PET biodistribution between Japanese and non-Japanese individuals. In the second (reader) study, the comparability of visual reads performed by Japanese and US expert readers who followed the same training program was evaluated. Methods This article reports findings from two separate studies and datasets. In the dose and biodistribution study, whole-body distribution of 18 F-flortaucipir was assessed ( N = 9). Standardized uptake value ratios, normalized to the entire cerebellum, were calculated, and whole-body effective dose was calculated using a 73.7 kg bodyweight model. In the reader study (Study A27; I7E-AV-A27), five Japanese physicians visually interpreted 60 PET scans randomly selected from a previous US reader study (Study FR01; NCT03901092). Scan positivity was determined based on increased activity of 18 F-flortaucipir in posterolateral temporal, occipital, or parietal/precuneus regions with or without frontal activity. Each scan was visually interpreted by all Japanese readers, who determined whether scans were consistent with an AD or non-AD pattern. Concordance between Japanese and US readers who underwent the same training on the interpretation of 18 F-flortaucipir PET images was then evaluated (reader study primary endpoint). Results The biodistribution of 18 F-flortaucipir was consistent between Japanese and non-Japanese individuals. When interpreting 18 F-flortaucipir PET images to distinguish between AD versus non-AD patterns, Japanese and US readers who underwent the same training showed 100% agreement on the majority reads, with a Cohen’s Kappa value of 1. Conclusions 18 F-flortaucipir whole-body biodistribution for Japanese individuals was consistent with that of non-Japanese individuals. After completing the same training, Japanese readers showed high concordance with US readers on the interpretation of 18 F-flortaucipir PET images to distinguish between AD and non-AD patterns. Data and scans were from previous studies registered with ClinicalTrials.gov (registration numbers: NCT04474405; NCT03901092).

Authors

Institutions

Publication Details

Journal
Annals of Nuclear Medicine
Published
2026-07-17
DOI
https://doi.org/10.1007/s12149-026-02239-4
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers

Etsuko Imabayashi, Eriko Kamiki, Anupa Arora, Amanda Morris et al.
Annals of Nuclear Medicine
Alzheimer's disease research and treatments
article

18F-flortaucipir PET imaging: Biodistribution in the Japanese population and diagnostic accuracy by Japanese readers

Etsuko Imabayashi, Eriko Kamiki, Anupa Arora, Amanda Morris, Leonardo Iaccarino, Ming Lu
article en

Abstract

Abstract Objective 18 F-flortaucipir (Tauvid™) is an 18 F-labeled diagnostic positron emission tomography (PET) radiopharmaceutical, which was developed to detect tau pathology in the brain and to estimate the density and/or distribution of aggregated tau neurofibrillary tangles for patients being evaluated for Alzheimer’s disease (AD). The objective of this article is to report findings from two studies. The primary objective of the first ( dose and biodistribution) study was to investigate the consistency of 18 F-flortaucipir PET biodistribution between Japanese and non-Japanese individuals. In the second (reader) study, the comparability of visual reads performed by Japanese and US expert readers who followed the same training program was evaluated. Methods This article reports findings from two separate studies and datasets. In the dose and biodistribution study, whole-body distribution of 18 F-flortaucipir was assessed ( N = 9). Standardized uptake value ratios, normalized to the entire cerebellum, were calculated, and whole-body effective dose was calculated using a 73.7 kg bodyweight model. In the reader study (Study A27; I7E-AV-A27), five Japanese physicians visually interpreted 60 PET scans randomly selected from a previous US reader study (Study FR01; NCT03901092). Scan positivity was determined based on increased activity of 18 F-flortaucipir in posterolateral temporal, occipital, or parietal/precuneus regions with or without frontal activity. Each scan was visually interpreted by all Japanese readers, who determined whether scans were consistent with an AD or non-AD pattern. Concordance between Japanese and US readers who underwent the same training on the interpretation of 18 F-flortaucipir PET images was then evaluated (reader study primary endpoint). Results The biodistribution of 18 F-flortaucipir was consistent between Japanese and non-Japanese individuals. When interpreting 18 F-flortaucipir PET images to distinguish between AD versus non-AD patterns, Japanese and US readers who underwent the same training showed 100% agreement on the majority reads, with a Cohen’s Kappa value of 1. Conclusions 18 F-flortaucipir whole-body biodistribution for Japanese individuals was consistent with that of non-Japanese individuals. After completing the same training, Japanese readers showed high concordance with US readers on the interpretation of 18 F-flortaucipir PET images to distinguish between AD and non-AD patterns. Data and scans were from previous studies registered with ClinicalTrials.gov (registration numbers: NCT04474405; NCT03901092).

Annals of Nuclear Medicine
Eli Lilly (United States) (US), Eli Lilly (Japan) (JP)
Eli Lilly and Company, Avid Radiopharmaceuticals
Quality Education
Openalex Percentile: Top 8%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.